NCT05594927招募中3 期
A Prospective, Randomized, Parallel-Controlled, Double-Blind, Double-Dummy, Multicenter, Phase III Clinical Trial of Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Beijing Shenogen Biomedical Co., Ltd3 个研究点 分布在 1 个国家目标入组 261 人开始时间: 2022年12月12日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 261
- 试验地点
- 3
- 主要终点
- Overall survival (OS)
研究概览
简要总结
A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.
详细描述
This is a prospective, randomized, parallel-controlled, double-blind, double-dummy, multicenter, phase III clinical trial. Patients with poor conditions and biomarker enrichment will be randomly assigned in a 2:1 ratio to receive either icaritin or huachansu as the first-line treatment until unacceptable toxic effects and loss of clinical benefit. A total of 261 participants with 206 deaths are required. The primary endpoint is overall survival (OS) in the full analysis set (FAS) population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 years and older;
- •HCC patients who meet the clinical diagnostic criteria of the Chinese Diagnosis and Treatment Guideline of Primary Liver Cancer (2022 edition), and/or with diagnosis confirmed histopathologically/cytologically;
- •Unresectable HCC patients;
- •Patients with a peripheral blood composite biomarker Score ≥ 2 points, 1 point each for AFP ≥ 400 ng/mL, TNF-α < 2.5 pg/mL, and IFN-γ ≥ 7.0 pg/mL ;
- •No prior first-line systemic treatment for HCC, including sorafenib, lenvatinib, donafenib, atezolizumab plus bevacizumab, sintilimab plus a bevacizumab biosimilar, camrelizumab plus apatinib, and durvalumab plus tremelimumab, oxaliplatin-based systemic chemotherapy (FOLFOX4) , icaritin, huachansu, and other anti-cancer drugs such as targeted agents, immune checkpoint inhibitors, and systemic chemotherapy;
- •Child-Pugh score ≤ 7;
- •Vital organ functions should meet the following requirements:
- •① Hematopoietic function: platelet ≥ 40×10^9/L, hemoglobin ≥ 80 g/L, white blood cell ≥ 2.0×10^9/L;
- •② Liver function: total bilirubin ≤ 1.5 times upper limit of normal (ULN) , alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) ≤ 5×ULN; albumin ≥ 28 g/L;
- •③ Renal function: Serum Creatinine ≤ 1.5×ULN, or creatinine clearance rate ≥ 50 mL/min;
- •If HBV-DNA ≥ 10^4 copies/mL (2000 IU/mL), antiviral and liver protection therapy must be used before enrollment, until HBV-DNA < 10^4 copies/mL (2000 IU/mL). In which case, the antiviral drugs should be administered continuously and liver function and hepatitis B virus load will be monitored during the study period;
- •Patients who meet one of two conditions: (A) are not or less appropriate candidates for first-line standard treatments recommended by the guidelines; (B) are not willing to receive first-line standard treatments recommended by the guidelines.
- •Surgical resection ended > 3 months, local ablation, hepatic artery intervention or radiotherapy ended > 4 weeks before randomization (implantation of radioactive particles ended > 3 months) and relevant adverse reactions having recovered. Patients without extrahepatic spread must have radiographic evidence of disease progression after local treatment;
- •Patients who had previously received adjuvant systemic therapy after surgical resection experienced the first radiographic disease progression more than 6 months after withdrawal of adjuvant therapy will be eligible for enrollment;
- •Within 2 weeks prior to randomization, no treatment with modern Chinese traditional medicine preparations with anti-tumor indications (refer to the 11th inclusion criterion when huaier granule was used as systemic adjuvant therapy), immunomodulators such as interferon-α and thymalfasin, tumor vaccines and cellular immunotherapy;
- •No blood transfusion or infusion of blood products, no use of hematopoietic growth factors (such as granulocyte colony-stimulating factor G-CSF), and no albumin infusion within 2 weeks prior to randomization;
- •≥1 measurable lesion according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.1), defined as a non-lymphoid lesion with the longest diameter ≥ 10 mm or a lymph node lesion with the short axis ≥ 15 mm; a lesion after previous radiotherapy or other loco-regional therapy which has been demonstrated progression confirmed per RECIST v1.1 with the longest diameter ≥ 10 mm scanned by dynamic-enhanced CT/ dynamic-enhanced MRI is to be deemed as a measurable lesion.
- •Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 or 1;
- •Expected survival of ≥ 12 weeks;
- •Female patients of childbearing age with a negative blood pregnancy within the first 7 days prior to randomization will be eligible; Female patients of childbearing age or male patients with female sexual partners of childbearing age should take effective contraceptive measures throughout treatment and within 3 months after the last dose;
- •Voluntary agreement to sign informed consent and the willingness and ability to comply with protocol schedules and testing;
- •No treatment with any other investigational drugs or medical devices within 4 weeks prior to randomization.
排除标准
- •Tumor occupancy ≥ 70% of liver, or tumor thrombus occupancy ≥ 50% of the main trunk of portal vein, or mesenteric vein or inferior vena cava tumor thrombus;
- •Moderate-to-severe ascites, i.e., the score of the indicator is > 2; Moderate-to-severe, or symptomatic pleural effusion and pericardial effusion requiring drainage;
- •Receipt of major surgery (craniotomy, thoracotomy, laparotomy, hip replacement, etc.) within 28 days prior to randomization or planned to receive major surgery during the study;
- •Other types of primary liver cancer, such as intrahepatic cholangiocarcinoma, mixed HCC and cholangiocarcinoma, fibrolamellar HCC, etc. Other malignancies within 5 years prior to signing the informed consent form or at present, excluding radically treated basal cell carcinoma of skin, squamous cell carcinoma of skin and/or radically resected carcinoma in situ;
- •Pregnant or lactating women;
- •Grade 2 or above myocardial ischemia or myocardial infarction (NCI-CTCAE v5.0), poorly-controlled arrhythmia, and/or New York Heart Association (NYHA) class III or IV cardiac insufficiency;
- •Patients who previously received allogeneic transplantation including liver transplantation, or plan to undergo liver transplantation during the study;
- •History of hepatic encephalopathy and/or hepatic nephropathy within 6 months prior to signing informed consent ;
- •HCV-RNA positive, ALT and/or AST > 2×ULN;
- •Human immunodeficiency virus (HIV) antibody positive;
- •Severe infection (≥ Grade 3 of NCI-CTCAE v5.0 criteria) at randomization;
- •Unable to swallow, chronic diarrhea or intestinal obstruction, which will significantly affect oral administration and absorption of the study drug;
- •History of gastrointestinal hemorrhage within 6 months before signing informed consent, or with clear tendency for gastrointestinal hemorrhage at present, such as: local active ulcers, stool occult blood ≥ 2+ or positive at two consecutive tests (attention should be paid to exclude the influence of food, drugs and other diseases);
- •Active autoimmune diseases requiring systemic treatment (e.g., NSAIDs, immunosuppressants, biologics, corticosteroids, etc.) except for patients receiving replacement therapy (e.g., hypothyroidism treated with thyroxine, type 1 diabetes mellitus treated with insulin, adrenal or pituitary insufficiency treated with physiologic corticosteroids, etc.);
- •Known central nervous system (CNS) metastasis; patients suspected of CNS metastasis need to undergo cerebral MRI/CT for exclusion;
- •Significant coagulation function abnormalities: international standardized ratio (INR) > 1.5 or prothrombin time (PT) > 16 s;
- •History of schizophrenia or psychiatric drug abuse;
- •Known allergy or intolerance to any ingredients of icaritin or huachansu preparations;
- •Other conditions that the investigator considers inappropriate for participation in this study.
研究组 & 干预措施
Icaritin soft capsule
Experimental
干预措施: Icaritin (Drug)
Huachansu tablet
Active Comparator
干预措施: Huachansu (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: From randomization to death from any cause, assessed up to approximately 24 months
Defined as the time from randomization to death from any cause
次要结局
- Progression--free survival (PFS)(From randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), assessed up to approximately 24 months)
- Objective response rate (ORR)(Up to approximately 24 months after randomization)
- Trough plasma concentration (Cmin）(Pre-dose at the end of cycle1 (Cycle length=28 days))
- 9/12/18-month overall survival (OS) rate(From randomization to 9, 12 and 18 months later)
- Disease control rate (DCR)(Up to approximately 24 months after randomization)
- Mean area under the concentration-time curve during the dosing interval (AUC0-t)(Within 0.5 h before dosing (0 h) and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, and 12 h after dosing at the end of cycle1 (Cycle length=28 days))
- Time to progression (TTP)(From randomization to the first occurrence of disease progression, assessed up to approximately 24 months)
- Time to deterioration (TTD)(From randomization to first deterioration, assessed up to approximately 24 months)
- Adverse events (AEs)(Up to approximately 24 months after randomization)
- Maximum plasma concentration (Cmax)(Post-dose at the end of cycle1 (Cycle length=28 days))
研究者
研究点 (3)
Loading locations...
相似试验
终止
2 期
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine CarcinomaNeuroendocrine CarcinomaNCT03168594Peking University66
已完成
1 期
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerNCT03290937M.D. Anderson Cancer Center34
已完成
2 期
Irinotecan Study For Cervical CancerUterine Cervical NeoplasmsNCT00136955Pfizer41
已完成
2 期
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular CarcinomaCarcinoma, HepatocellularNCT00635323Pfizer73
Unknown
4 期
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung AdenocarcinomaEGFR Positive Non-small Cell Lung CancerAdenocarcinomaNCT01665417Betta Pharmaceuticals Co., Ltd.100